1. Scrip
  2. >>Conferences
  3. >>ASCO

ASCO: DESTINY-Breast09 Strong, But May Need Mature OS Data To Change Practice

AI, Biomarkers Could Help Predict Enhertu Toxicity

 
• By Alaric DeArment

Data from AstraZeneca/Daiichi’s breast cancer trial showed positive PFS, but some oncologists are waiting for confirmation of statistically significant OS benefit.

(Alaric DeArment)

AstraZeneca and Daiichi Sankyo’s HER2-targeting antibody-drug conjugate Enhertu (trastuzumab deruxtecan), used in combination with Roche’s HER2-targeting Perjeta (pertuzumab), has potential to change practice in first-line HER2-positive metastatic breast cancer, but some oncologists may want to see more mature overall survival (OS) data before they make that determination.

Key Takeaways
  • AstraZeneca and Daiichi Sankyo presented positive data from the DESTINY-Breast09 trial at ASCO that showed a 44% reduction in the risk of progression or death in HER2-positive metastatic breast cancer in the first line.

The results from the Phase III DESTINY-Breast09 trial, presented June 2 as a late-breaking abstract at the American Society of...

More from ASCO

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

 
• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Innovent Builds Metabolic Pipeline While Retaining Oncology Backbone

 
• By Xu Hu

Innovent presented data on multiple pipeline assets at ASCO, including promising OS results for its first-in-class anti-PD-1/IL-2α-bias bispecific. The Chinese firm is also continuing to build out its metabolic disease portfolio and consider its partnering strategies, its CEO tells Scrip.

Henlius CEO Details PD-L1 ADC’s Path To 1L Mono/Combo Therapy

 
• By Dexter Jie Yan

Henlius is investigating the optimum dose for its PD-L1-targeting antibody-drug conjugate HLX43 to support potential first-line use, its CEO explains to Scrip.

More from R&D

Exelixis Positions Zanzalintinib For Post-Cabozantinib LOE Future

 
• By Alaric DeArment

The company announced positive Phase III data in previously treated colorectal cancer for zanzalintinib and it could see sales of more than $1bn in that indication.

Merck & Co.’s Winrevair Positioned For Expansion On HYPERION Results

 
• By Jessica Merrill

The Phase III trial met the primary endpoint of time to clinical worsening in patients newly diagnosed with pulmonary arterial hypertension.

Novo And Lilly Lay Out Patient Segmentation Plans For Obesity Treatment

 
• By Andrew McConaghie

As competition heats up and the obesity market matures, the two frontrunners are tailoring their studies to the wants and needs of different patient groups.